甘露聚糖肽序贯疗法与放射治疗、化学治疗联合应用对直肠癌的疗效观察

摘要

Objective:To observe the clinical efficacy of Mannatide sequential therapy combined with radiotherapy and chemotherapy to treat rectal cancer.Methods:60 patients with rectal cancer were randomly divided into experimental and control groups. The two groups were given conventional treatment-chemotherapy program of CapeOX:on the first day,use oxaliplatin 130mg/m2;and capecitabine 850mg/m2,2 times a day for 14 days;every 3 weeks for a cycle,and applied two cycles.The experimental group on the basis of conventional treatment accepted Mannatide sequential treatment;and the control group accepted thymosin sequential treatment control group accepted on the basis of conventional therapy.Count the patients’ quality of life, detect the immune indexes and record adverse reactions.Results:Mannatide can prolong median survival time of the experimental group and significantly improve Karnofsky score one year after the end of treatment.There is significant difference compared with the control group (P<0.05).Immune indexes were improved compared to that before treatment.There is significant difference between experiment group and control group with the CD4/CD8 (ratio) [(1.57±0.39) than (1.42±0.30),P<0.05);and the NK cells,neutrophils levels showed significant difference (P=0.038 and P=0.042). Conclusion:The method of Mannatide sequential treatment combined with radiotherapy and chemotherapy to treat rectal cancer can significantly improve the quality of life of patients,comprehensively enhance the immune function of patients,and reduce the side effects of radiotherapy and chemotherapy.The clinical effect of Mannatide sequential therapy is better than thymosin sequential therapy.%目的：观察甘露聚糖肽疗法与放射治疗、化学治疗(放化疗)联合应用治疗直肠癌的临床疗效。方法：将60例直肠癌患者随机平均分为试验组和对照组。两组均给予常规治疗--化疗CapeOX方案：奥沙利铂,130mg/m2,第一天；卡培他滨,850mg/m2,每日2次,持续14天；每3周为一周期,连用2个周期。试验组在常规治疗基础上接受甘露聚糖肽序贯治疗；对照组在常规治疗基础上接受胸腺肽序贯治疗。统计患者生存质量,测定免疫学指标以及记录不良反应。结果：治疗后试验组甘露聚糖肽能延长患者的中位生存期,显著提高治疗结束后1年的卡氏评分,与对照组相比有显著性差异(P<0.05)；免疫指标较治疗前均有所改善,试验组CD4/CD8(比值)较对照组具有显著性差异[(1.57±0.39)比(1.42±0.30),P<0.05],NK细胞、中性粒细胞水平亦有显著性差异(P=0.038和P=0.042)。结论：甘露聚糖肽序贯治疗与放化疗联合应用,治疗晚期直肠癌,可显著提高患者生存质量,全面增强患者免疫功能,减低放化疗带来的副作用,效果优于胸腺肽序贯治疗。